Landos Biopharma — Investor Presentation (February 2023)
21 slides from Landos Biopharma's investor presentation, Feb 28, 2023

Slide 1: Corporate Overview
Corporate Overview February 28, 2023 Clinical stage biopharmaceutical company focused on the development of first-in-class therapeutics for patients with autoimmune disease. Exhibit 99.3

Slide 2: Forward-looking statements
This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, prospects, plans and objectives of manage

Slide 3: Landos' Path Forward
SINGULAR FOCUS on advancing clinical development of NX-13 in Ulcerative Colitis (UC) NX-13 is a potential GAMECHANGER, with a novel mechanism of action (MOA), impressive safety profile, once-daily dosing with promising and early signals of clinical improvement (as soon as 2 weeks in patients’ sympto

Slide 4: Landos' Novel Immunology Portfolio
Landos’ Novel Immunology Portfolio 2 8 4 Novel target (NLRX1 and PLXDC2) libraries of immunometabolic modulation pathways Potentially first-in-class, once-daily, oral therapeutics upstream of multiple canonical inflammatory/ regulatory pathways Indications in the immunology space targeted by broadly

Slide 5: Broad Portfolio of Clinical & Pre-clinical Programs
Broad Portfolio of Clinical & Pre-clinical Programs NX-13 (entering Phase 2 for UC): Novel, oral, gut-selective NLRX1 agonist in development for the treatment of Ulcerative Colitis and Crohn’s Disease as a once-daily treatment LABP-66 (pre-clinical): Novel, oral, once-daily, product candidate target

Slide 6: Landos Strategy: Advancing NX-13 in UC is the Company's Focus
6 Landos Strategy: Advancing NX-13 in UC is the Company’s Focus *NX-13 Phase 1b study was not designed or powered for exploratory clinical endpoints therefore results are hypothesis-generating only NX-13 is the Top Priority Impressive & Emerging Data Foundation Supports Dual Focus Clear Path Forward

Slide 7: UC is an Attractive & Growing Market Opportunity
Global Sales ($M): 2020 and 2030 UC is an Attractive & Growing Market Opportunity Source: Clarivate 2020 2030 Global UC Diagnosed Patients: 2020 – 2030 Source: Clarivate Source: 2022 Decision Resource Group (Clarivate) UC Disease Landscape and Forecast including 2030 projected data Global UC Sales (

Slide 8: NX-13 Poised for Broad Utilization in both Early & Late-Stage Disease
Aminosalicylates (5-ASA) Mesalamine, Sulfasalazine Immunosuppressants Methotrexate, thiopurines Corticosteroids Budesonide, Prednisone Alpha-4-beta-7 integrin Entyvio TNF-alpha inhibitors Humira, Remicade, Cimzia IL-12/IL-23 Oral Approaches S1P1, JAK, miRNA Pathways MILD MODERATE SEVERE NX-13 Poised

Slide 9: NLRX1 Library
NLRX1 Library

Slide 10: NLRX1 Activation Reduces Inflammatory Cytokines, Cells & Signaling Pathways
NLRX1 Activation Reduces Inflammatory Cytokines, Cells & Signaling Pathways

Slide 11: NX-13 Profile
NX-13 Profile Mechanism of Action Drug Profile Recent & Upcoming Milestones Targets NLRX1 pathway, a mitochondrial-associated regulatory NOD-like receptor Bimodal MOA aims to decrease reactive oxygen species and oxidative stress, while decreasing pro-inflammatory signals No on-target toxicities asso

Slide 12: Phase 1b Study Design of NX-13 in Active UC
Phase 1b Study Design of NX-13 in Active UC IR = Immediate Release; MR = Modified Release Note: Study was not designed or powered for exploratory clinical endpoints therefore results are hypothesis-generating only Group 1: NX-13 250mg IR n=12 Group 4: Placebo n = 4 Week 2 Week 4 EOT Group 3: NX-13 5

Slide 13: Phase 1b Results: Reductions in Multiple Clinical Measures after 4 weeks
Clinical Response Defined as CFB of at least -3, or -30% in Mayo Score Histologic Remission Geboes <3.1, no increased neutrophils in the LP Endoscopic Response MES CFB of at least -1 Phase 1b Results: NX-13 Treated Patients Experienced Reductions in Multiple Clinical Measures after 4 weeks IR= Immed

Slide 14: Phase 1b Results: Symptomatic Remission in Rectal Bleeding & Stool Frequency
Patients in the 250mg group had the greatest reduction of Rectal Bleeding and Stool Frequency at 2 weeks, with further reduction at 4 weeks Majority of patients saw complete resolution of BOTH rectal bleeding and stool frequency after 4 weeks of treatment with NX-13 250mg, once daily Phase 1b Result

Slide 15: Phase 1b Results: NX-13 Well-Tolerated with Promising Signs of Clinical Improvement
Generally well tolerated, consistent with non-clinical, Phase 1a data No Serious Adverse Events 3 unrelated Adverse Events (AEs) of note 4 weeks of low dose, immediate release, once daily treatment induced: Clinical response in 8/11 patients Clinical remission in 3/11 patients Endoscopic and Histolo

Slide 16: What's Next: Study Design for NX-13 Phase 2 Proof of Concept Trial
What’s Next: Study Design for NX-13 Phase 2 Proof of Concept Trial GOAL | Evaluate the safety, efficacy and pharmacokinetics of NX-13 in moderate to severe UC patients. TIMING | On-track to initiate Phase 2 trial in Q2 2023; Expecting to report topline data by Q4 2024 ADDITIONAL PHASE 2 LEARNINGS |

Slide 17: Preclinical Programs in the NLRX1 Agonist Library
Preclinical Programs in the NLRX1 Agonist Library 17 LABP-73 for Respiratory Inflammation LABP-66 for CNS Inflammation Key Indications Asthma, COPD MS, AlzD Administration Oral, once-daily Oral, once-daily Development Stage Preclinical Development Preclinical Development Additional Information MOA s

Slide 18: PLXDC2 Library
PLXDC2 Library B1OPHARMA

Slide 19: Activation of PLXDC2 Suppresses Inflammation & Angiogenesis
Activation of PLXDC2 in Immune & Non-Immune Cells Suppresses Inflammation & Angiogenesis

Slide 20: Preclinical Programs in the PLXDC2 Agonist Library
Preclinical Programs in the PLXDC2 Agonist Library 20 LABP-69 Key Indications Rheumatoid Arthritis (“RA”), Diabetic Nephropathy Administration Oral, once-daily Development Stage Preclinical Development Additional Information MOA: Designed to decrease reactive oxygen species, oxidative stress, pro-in

Slide 21: Landos Biopharma
LANDOS BIlOPHARMA
Source: SEC EDGAR · 8-K filed Feb 28, 2023




